Trials / Completed

CompletedNCT06877247

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 5 (actual)

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.

Conditions

Secondary Hyperparathyroidism

Interventions

Type	Name	Description
DRUG	[14C] SHR6508 Injection	\[14C\] SHR6508 injection.

Timeline

Start date: 2024-12-23
Primary completion: 2025-04-04
Completion: 2025-10-11
First posted: 2025-03-14
Last updated: 2026-03-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06877247. Inclusion in this directory is not an endorsement.